Loader

Pathways

PathWhiz ID Pathway Meta Data

PW126971

Pw126971 View Pathway
drug action

Sertaconazole Action Pathway

Homo sapiens
Sertaconazole is a topical antifungal agent used to treat interdigital tinea pedis (athelete's foot) in immunocompromised patients. Sertaconazole inhibits lanosterol 14-alpha demethylase in the endoplasmic reticulum of fungal cells. Lanosterol 14-alpha demethylase is the enzyme that catalyzes the synthesis of 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol from lanosterol. With this enzyme inhibited ergosterol synthesis cannot occur which causes a significant low concentration of ergosterol in the fungal cell. Ergosterol is essential in maintaining membrane integrity in fungi. Without ergosterol, the fungus cell cannot synthesize membranes thereby increasing fluidity and preventing growth of new cells. This leads to cell lysis which causes it to collapse and die. Sertaconazole might also inhibit endogenous respiration, interact with membrane phospholipids, inhibit transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.

PW145241

Pw145241 View Pathway
drug action

Sertaconazole Drug Metabolism Action Pathway

Homo sapiens

PW176403

Pw176403 View Pathway
metabolic

Sertaconazole Predicted Metabolism Pathway

Homo sapiens
Metabolites of Sertaconazole are predicted with biotransformer.

PW145657

Pw145657 View Pathway
drug action

Sertindole Drug Metabolism Action Pathway

Homo sapiens

PW176355

Pw176355 View Pathway
metabolic

Sertindole Predicted Metabolism Pathway

Homo sapiens
Metabolites of sildenafil are predicted with biotransformer.

PW126521

Pw126521 View Pathway
drug action

Sertraline Action Pathway (New)

Homo sapiens
Sertraline is a selective serotonin reuptake inhibitor (SSRI) indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope. It's mechanism of action it to bind selectively bind to the sodium dependent serotonin transporter and blocking the recycling of serotonin from the synapse. As serotonin accumulates it enhances the serotonergic function of the 5-hydroxytryptamine 1A receptor leading to decreased anxiety and depressive moods. Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.

PW145193

Pw145193 View Pathway
drug action

Sertraline Drug Metabolism Action Pathway

Homo sapiens

PW127973

Pw127973 View Pathway
drug action

Sertraline Mechanism of Action Action Pathway (New)

Homo sapiens
Sertraline is a selective serotonin reuptake inhibitor (SSRI) indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neuro cardiogenic syncope. Sertraline also has minimal effects on norepinephrine and dopamine uptake, and research has shown that it has more dopaminergic activity than other medications in the same SSRI class. Sertraline binds selectively bind to the sodium dependent serotonin transporter and blocks the recycling of serotonin from the synapse. As serotonin accumulates it enhances the serotonergic function of the 5-hydroxytryptamine 1A receptor leading to decreased anxiety and depressive moods. Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.

PW128111

Pw128111 View Pathway
drug action

Sertraline Mechanism of Action Action Pathway New

Homo sapiens
Sertraline is a selective serotonin reuptake inhibitor (SSRI) indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neuro cardiogenic syncope. Sertraline also has minimal effects on norepinephrine and dopamine uptake, and research has shown that it has more dopaminergic activity than other medications in the same SSRI class. Sertraline binds selectively bind to the sodium dependent serotonin transporter and blocks the recycling of serotonin from the synapse. As serotonin accumulates it enhances the serotonergic function of the 5-hydroxytryptamine 1A receptor leading to decreased anxiety and depressive moods. Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.

PW176135

Pw176135 View Pathway
metabolic

Sertraline Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Sertraline are predicted with biotransformer.